Darshan Drug House Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 0.40 M
as on 24-10-2024
- Company Age 31 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.50 M
as on 24-10-2024
- Revenue 11.43%
(FY 2023)
- Profit 64.19%
(FY 2023)
- Ebitda 18.49%
(FY 2023)
- Net Worth 19.29%
(FY 2023)
- Total Assets 2.63%
(FY 2023)
About Darshan Drug House
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.40 M.
The company currently has active open charges totaling ₹6.50 M.
Kamlesh Shah, Harshadray Shah, and Bharat Parekh serve as directors at the Company.
- CIN/LLPIN
U51397MH1993PTC070779
- Company No.
070779
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Feb 1993
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationNavi Mumbai, Maharashtra
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Darshan Drug House?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamlesh Shah  | Director | 12-Feb-1993 | Current |
| Harshadray Shah | Director | 12-Feb-1993 | Current |
| Bharat Parekh | Director | 01-Dec-2009 | Current |
Financial Performance of Darshan Drug House.
Darshan Drug House Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 11.43% increase. The company also saw a substantial improvement in profitability, with a 64.19% increase in profit. The company's net worth Soared by an impressive increase of 19.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Darshan Drug House?
In 2023, Darshan Drug House had a promoter holding of 81.25% and a public holding of 18.75%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Darshan Drug And Herbs Private LimitedActive 15 years 2 monthsKamlesh Shah and Harshadray Shah are mutual person
- Darshan Pharmacuticals Private LimitedActive 14 years 7 months
Kamlesh Shah and Harshadray Shah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Icici Bank Limited Creation Date: 18 May 2010 | ₹6.00 M | Open |
Co.Operative Bank Ahmedabad Ltd. Creation Date: 15 Jul 1994 | ₹0.50 M | Open |
How Many Employees Work at Darshan Drug House?
Unlock and access historical data on people associated with Darshan Drug House, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Darshan Drug House, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Darshan Drug House's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
